Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1126 to 1140 of 1315 results for long term conditions

  1. What are the service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated with better outcomes?

    service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated...

    Research recommendation
    Published
    26 October 2020

  2. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    26 August 2015
    View recommendations

    Sections for TA352

  3. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

    Medtech innovation briefing
    Published
    10 May 2022

  4. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

    Medtech innovation briefing
    Published
    4 February 2014

  5. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA337

  6. Cardiac rehabilitation:- Is an 8-week, comprehensive, multidisciplinary, cardiac rehabilitation service more clinically and cost effective for managing stable angina than current clinical practice?

    rehabilitation programmes are an established treatment strategy for certain heart conditions, such as for people who have had a heart...

    Research recommendation
    Published
    9 June 2015

  7. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.

    HealthTech guidance
    Published
    12 January 2023
    View recommendations

    Sections for HTG655

  8. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  9. Emotional and psychological support and interventions:- What emotional support do children and young people with life-limiting conditions and their parents or carers need, and how would they like these needs to be addressed?

    research recommendation

    Research recommendation
    Published
    1 November 2017

  10. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

    Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    25 September 2017
    View recommendations

    Sections for TA439

  11. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA209

  12. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

    HealthTech guidance
    Published
    20 August 2014
    View recommendations

    Sections for HTG348

  13. Blood pressure targets: What is the clinical and cost effectiveness of a lower blood pressure treatment target relative to the standard blood pressure treatment target for people with aneurysmal subarachnoid haemorrhage?

    other conditions after discharge from hospital. Full details of the evidence and the committee's discussion are in evidence review Q:...

    Research recommendation
    Published
    12 December 2022

  14. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  15. Extracorporeal carbon dioxide removal for acute respiratory failure (HTG703)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.

    HealthTech guidance
    Published
    15 November 2023
    View recommendations

    Sections for HTG703